Beactica is a drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. We offer expertise and services in the area of SPR biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using our proprietary Sprint™ platform.

Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR biosensor-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes.

Latest News


Upcoming events

31 August - 4 September, Beactica's CSO will present at the 20th EuroQSAR conference (Understanding Chemical-Biological Interactions) in St Petersburg, Russia. The title of the keynote lecture is "Lead Dicscovery and Optimisation by Use of Interaction Kinetic Analysis".